Continuous subcutaneous apomorphine infusion does not impair the dynamics of cognitive action control in mild to moderate Parkinson’s disease | Zendy

Joan Duprez | Zendy; JeanFrançois Houvenaghel | Zendy; Sophie Drapier | Zendy; Ma Auffret | Zendy; Dominique Drapier | Zendy; Guillaume Robert | Zendy; Marc Vérin | Zendy; Paul Sauleau | Zendy

Open Access

Continuous subcutaneous apomorphine infusion does not impair the dynamics of cognitive action control in mild to moderate Parkinson’s disease

Author(s) -

Joan Duprez,

JeanFrançois Houvenaghel,

Sophie Drapier,

Ma Auffret,

Dominique Drapier,

Guillaume Robert,

Marc Vérin,

Paul Sauleau

Publication year - 2017

Publication title -

journal of neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.541

H-Index - 136

eISSN - 1432-1459

pISSN - 0340-5354

DOI - 10.1007/s00415-017-8721-7

Subject(s) - cognition , apomorphine , psychology , parkinson's disease , subthalamic nucleus , neurology , deep brain stimulation , audiology , medicine , disease , neuroscience , dopamine , dopaminergic

Continuous subcutaneous apomorphine infusion (CSAI) is increasingly used in Parkinson's disease (PD), notably in patients contraindicated for subthalamic deep brain stimulation. Although it has been suggested that CSAI is safe regarding cognition, few studies have actually investigated its effect, especially on cognitive control which is a crucial process for goal-directed behavior. More specifically, its impact on the dynamics of cognitive action control, as reflected by the activation and suppression of impulsive responses, has yet to be investigated, which is the objective of the present study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research